(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of 73.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.34%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.17%.
Nanobiotix Sa's revenue in 2026 is $11,950,588.On average, 7 Wall Street analysts forecast NBTX's revenue for 2026 to be $3,384,526,021, with the lowest NBTX revenue forecast at $709,079,064, and the highest NBTX revenue forecast at $5,986,653,238. On average, 6 Wall Street analysts forecast NBTX's revenue for 2027 to be $2,083,390,057, with the lowest NBTX revenue forecast at $567,263,251, and the highest NBTX revenue forecast at $3,615,049,071.
In 2028, NBTX is forecast to generate $3,557,840,380 in revenue, with the lowest revenue forecast at $197,963,298 and the highest revenue forecast at $7,664,807,022.